Omeros (OMER) Inventory (2014 - 2026)
Omeros' (OMER) quarterly Inventory came in at $183000.0 in Q1 2026, down 74.3% quarter-over-quarter from $712000.0 in Q3 2021.
Omeros (OMER) Inventory (2014 - 2026) Analysis & Trends
Omeros has disclosed Inventory across 9 years of filings, most recently posting $183000.0 for Q1 2026.
- Inventory for Q1 2026 came in at $183000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $183000.0 (changed N/A YoY), and the FY2020 annual result was $1.4 million, up 18.13% from the prior year.
- Inventory came in at $183000.0 for Q1 2026 at Omeros, down from $712000.0 in the prior quarter.
- In the past five years, Inventory ranged from a high of $183000.0 in Q1 2026 to a low of $183000.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 32.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.77 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | 183,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 183,000.00 |
| Sep 30, 2021 | 712,000.00 |
| Jun 30, 2021 | 978,000.00 |
| Mar 31, 2021 | 1.19 Mn |
| Dec 31, 2020 | 1.36 Mn |
| Sep 30, 2020 | 1.54 Mn |
| Jun 30, 2020 | 1.89 Mn |
| Mar 31, 2020 | 1.21 Mn |
| Dec 31, 2019 | 1.15 Mn |
| Sep 30, 2019 | 1.17 Mn |
| Jun 30, 2019 | 1.19 Mn |
| Mar 31, 2019 | 736,000.00 |
| Dec 31, 2018 | 88,000.00 |
| Sep 30, 2018 | 214,000.00 |
| Jun 30, 2018 | 235,000.00 |
| Mar 31, 2018 | 247,000.00 |
| Dec 31, 2017 | 443,000.00 |
| Sep 30, 2017 | 822,000.00 |
| Jun 30, 2017 | 905,000.00 |
| Mar 31, 2017 | 960,000.00 |